DIA
CYTK icon

Dana Investment Advisors’s Cytokinetics CYTK Stock Holding History

Dana Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
20,734
+4,973
+32% +$357K 0.05% 356
2026
Q1 		$1.04M Buy
15,761
+385
+3% +$24.5K 0.03% 400
2025
Q4 		$977K Sell
15,376
-2,037
-12% -$127K 0.03% 393
2025
Q3 		$957K Buy
17,413
+811
+5% +$33.4K 0.03% 397
2025
Q2 		$549K Sell
16,602
-401
-2% -$13.9K 0.02% 444
2025
Q1 		$683K Buy
17,003
+140
+0.8% +$6.43K 0.02% 415
2024
Q4 		$793K Sell
16,863
-169
-1% -$8.78K 0.03% 415
2024
Q3 		$899K Buy
17,032
+1,082
+7% +$60.3K 0.03% 393
2024
Q2 		$864K Sell
15,950
-35
-0.2% -$2.11K 0.03% 390
2024
Q1 		$1.12M Sell
15,985
-1,136
-7% -$87.9K 0.04% 361
2023
Q4 		$1.43M Sell
17,121
-1,295
-7% -$46.9K 0.07% 208
2023
Q3 		$543K Sell
18,416
-1,829
-9% -$60.9K 0.03% 298
2023
Q2 		$660K Buy
20,245
+295
+1% +$10.9K 0.03% 286
2023
Q1 		$702K Buy
19,950
+1,349
+7% +$55K 0.04% 278
2022
Q4 		$852K Buy
18,601
+2,994
+19% +$129K 0.04% 250
2022
Q3 		$756K Sell
15,607
-211
-1% -$10.2K 0.04% 252
2022
Q2 		$621K Sell
15,818
-1,533
-9% -$61.7K 0.03% 287
2022
Q1 		$639K Buy
17,351
+489
+3% +$17.4K 0.03% 251
2021
Q4 		$769K Sell
16,862
-2,483
-13% -$95.8K 0.03% 232
2021
Q3 		$691K Sell
19,345
-5,866
-23% -$173K 0.03% 228
2021
Q2 		$499K Sell
25,211
-111
-0.4% -$2.61K 0.02% 250
2021
Q1 		$589K Buy
+25,322
New +$541K 0.03% 242

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dana Investment Advisors's CYTK Position: Q2 2026 in Review

Dana Investment Advisors increased its Cytokinetics (CYTK) stake by 32% in Q2 2026, buying an estimated $357K and bringing the position to 20,734 shares worth $1.77M. The position accounts for 0.05% of the portfolio, ranked #356.

Dana Investment Advisors first reported a position in CYTK in Q1 2021 and has held it in 22 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Dana Investment Advisors held 20,734 shares of Cytokinetics worth $1.77M as of Q2 2026.
  • Dana Investment Advisors bought 4,973 Cytokinetics shares in Q2 2026, an estimated $357K.
  • Cytokinetics made up 0.05% of Dana Investment Advisors's portfolio in Q2 2026, its #356 holding.
  • Dana Investment Advisors first reported a position in Cytokinetics in Q1 2021 and has held it in 22 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Dana Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.